Regeneus Ltd. (RGS) reported that its cash position at 30 June is $1.09 million. The sources of funding for the Company over the next 18 months include: milestone payments and anticipated clinical licensing opportunities for Progenza; shareholder loan repayments relating to the funding of employee options exercised as part of the IPO in 2013; the R&D tax incentive for FY'18 including forward funding arrangements where necessary and options exercised. These sources of cash are expected to provide sufficient funding to support the Company's R&D, clinical trials and operating activities for FY'19 and into FY'20.
